Facultad de Medicina (FM)
Centro académico
Tel Aviv Sourasky Medical Center
Tel Aviv, IsraelPublicaciones en colaboración con investigadores/as de Tel Aviv Sourasky Medical Center (10)
2024
-
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029
2023
-
Long-term safety of spinal cord stimulation systems in a prospective, global registry of patients with chronic pain
Pain Management, Vol. 13, Núm. 2, pp. 115-127
-
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Leukemia Research, Vol. 134
2021
-
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
2018
-
Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO
Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
2015
-
Role of Systemic Anti-Tumor Necrosis Factor Alpha Treatment in the Reduction of Proliferative Vitreoretinopathy
Journal of Clinical & Experimental Ophthalmology, Vol. 06, Núm. 04